The House of Representatives passed a bill on Wednesday that backs new FDA authority over drug safety, including allowing the FDA to require new studies, order label changes and monitor drugs on the market. The bill also renews for five years two programs to collect user fees from drug and medical device manufacturers.

Related Summaries